Alpha interferon restricts human T-lymphotropic virus type 1 and 2 De Novo infection through PKR activation

Journal of Virology

Volumn 87, Issue 24, 2013, Pages 13386-13396

  Cachat, Anne ^a,b   Chevalier, Sébastien Alain ^a,b   Alais, Sandrine ^a,b   Ko, Nga Ling ^c   Ratner, Lee ^d   Journo, Chloé ^a,b   Dutartre, Hélène ^a,b   Mahieux, Renaud ^a,b  

^a UNIVERSITÉ DE LYON   (France)

^b UNIVERSITÉ LYON 1   (France)

^c INSTITUT PASTEUR   (France)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA1 INTERFERON; CYTOKINE; GAG PROTEIN; SMALL INTERFERING RNA; TAX PROTEIN; VIRUS ENVELOPE PROTEIN;

ARTICLE; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 2; HUMAN T CELL LEUKEMIA VIRUS INFECTION; INNATE IMMUNITY; LYMPHOCYTE; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; PSEUDOTYPING; T LYMPHOCYTE; VIRUS REPLICATION;

CELL LINE; EIF-2 KINASE; ENZYME ACTIVATION; HOST-PATHOGEN INTERACTIONS; HTLV-I INFECTIONS; HTLV-II INFECTIONS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMAN T-LYMPHOTROPIC VIRUS 2; HUMANS; INTERFERON-ALPHA; RECOMBINANT PROTEINS;

EID: 84888057444     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02758-13     Document Type: Article

References (68)

1. Gessain A, Cassar O. 2012. Epidemiological aspects and world distribution of HTLV-1 infection. Front. Microbiol. 3:388.
2. Anonymous. 1988. The third nation-wide study on adult T-cell leukemia/ lymphoma (ATL) in Japan:characteristic patterns of HLA antigen and HTLV-I infection in ATL patients and their relatives. The T-and B-cell Malignancy Study Group. Int. J. Cancer 41:505-512.
3. Gessain A, Barin F, Vernant JC, Gout O, Maurs L, Calender A, de The G. 1985. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet ii:407-410.
4. Osame M, Usuku K, Izumo S, Ijichi N, Amitani H, Igata A, Matsumoto M, Tara M. 1986. HTLV-I associated myelopathy, a new clinical entity. Lancet i:1031-1032.
5. Takatsuki T. 1977. Adult T-cell leukemia in Japan, p 73-77. In Seno S, Irino S (ed), Topics in hematology. Excerpta Medica, Amsterdam, The Netherlands.
6. Murphy EL, Fridey J, Smith JW, Engstrom J, Sacher RA, Miller K, Gibble J, Stevens J, Thomson R, Hansma D, Kaplan J, Khabbaz R, Nemo G. 1997. HTLV-associated myelopathy in a cohort of HTLV-I and HTLV-II-infected blood donors. The REDS investigators. Neurology 48:315-320.
7. Bartman MT, Kaidarova Z, Hirschkorn D, Sacher RA, Fridey J, Garratty G, Gibble J, Smith JW, Newman B, Yeo AE, Murphy EL. 2008. Long-term increases in lymphocytes and platelets in human Tlymphotropic virus type II infection. Blood 112:3995-4002.
8. Feuer G, Green PL. 2005. Comparative biology of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2. Oncogene 24:5996-6004.
9. Kannian P, Green PL. 2010. Human T lymphotropic virus type 1 (HTLV-1):molecular biology and oncogenesis. Viruses 2:2037-2077.
10. Rende F, Cavallari I, Romanelli MG, Diani E, Bertazzoni U Ciminale V. 2012. Comparison of the genetic organization, expression strategies and oncogenic potential of HTLV-1 and HTLV-2. Leuk/Res. Treatment 2012:876153.
11. Isaacs A, Lindenmann J. 1957. Virus interference. I. The interferon. Proc. R Soc. Lond. B Biol. Sci. 147:258-267.
12. de Weerd NA, Nguyen T. 2012. The interferons and their receptors- distribution and regulation. Immunol. Cell Biol. 90:483-491.
13. Sadler AJ, Williams BR. 2008. Interferon-inducible antiviral effectors. Nat. Rev. Immunol. 8:559-568.
14. Wang BX, Fish EN. 2012. The yin and yang of viruses and interferons. Trends Immunol. 33:190-197.
15. Colisson R, Barblu L, Gras C, Raynaud F, Hadj-Slimane R, Pique C, Hermine O, Lepelletier Y, Herbeuval JP. 2010. Free HTLV-1 induces TLR7-dependent innate immune response and TRAIL relocalization in killer plasmacytoid dendritic cells. Blood 115:2177-2185.
16. Hishizawa M, Imada K, Kitawaki T, Ueda M, Kadowaki N, Uchiyama T. 2004. Depletion and impaired interferon-alpha-producing capacity of blood plasmacytoid dendritic cells in human T-cell leukaemia virus type I-infected individuals. Br. J. Haematol. 125:568-575.
17. Gill PS, Harrington W, Jr, Kaplan MH, Ribeiro RC, Bennett JM, Liebman HA, Bernstein-Singer M, Espina BM, Cabral L, Allen S, Kornblau S, Pike MC, Levine AM. 1995. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N. Engl. J. Med. 332:1744-1748.
18. Hermine O, Allard I, Levy V, Arnulf B, Gessain A, Bazarbachi A. 2002. A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/ lymphoma. Hematol. J. 3:276-282.
19. Hermine O, Bouscary D, Gessain A, Turlure P, Leblond V, Franck N, Buzyn-Veil A, Rio B, Macintyre E, Dreyfus F, Bazarbachi A. 1995. Treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N. Engl. J. Med. 332:1749-1751.
20. Matutes E, Taylor GP, Cavenagh J, Pagliuca A, Bareford D, Domingo A, Hamblin M, Kelsey S, Mir N, Reilly JT. 2001. Interferon alpha and zidovudine therapy in adult T-cell leukaemia lymphoma:response and outcome in 15 patients. Br. J. Haematol. 113:779-784.
21. Ratner L, Harrington W, Feng X, Grant C, Jacobson S, Noy A, Sparano J, Lee J, Ambinder R, Campbell N, Lairmore M. 2009. Human T cell leukemia virus reactivation with progression of adult T-cell leukemialymphoma. PLoS One 4:e4420. doi:10.1371/journal.pone.0004420.
22. White JD, Wharfe G, Stewart DM, Maher VE, Eicher D, Herring B, Derby M, Jackson-Booth PG, Marshall M, Lucy D, Jain A, Cranston B, Hanchard B, Lee CC, Top LE, Fleisher TA, Nelson DL, Waldmann TA. 2001. The combination of zidovudine and interferon alpha-2B in the treatment of adult T-cell leukemia/lymphoma. Leuk. Lymphoma 40:287-294.
23. Arimura K, Nakagawa M, Izumo S, Usuku K, Itoyama Y, Kira J, Osame M. 2007. Safety and efficacy of interferon-alpha in 167 patients with human T-cell lymphotropic virus type 1-associated myelopathy. J. Neurovirol. 13:364-372.
24. Izumo S, Goto I, Itoyama Y, Okajima T, Watanabe S, Kuroda Y, Araki S, Mori M, Nagataki S, Matsukura S, Akamine T, Nakagawa M, Yamamoto I, Osame M. 1996. Interferon-alpha is effective in HTLV-Iassociated myelopathy:a multicenter, randomized, double-blind, controlled trial. Neurology 46:1016-1021.
25. Kuroda Y, Kurohara K, Fujiyama F, Takashima H, Endo C, Matsui M, Neshige R, Kakigi R. 1992. Systemic interferon-alpha in the treatment of HTLV-I-associated myelopathy. Acta Neurol. Scand. 86:82-86.
26. Nakagawa M, Nakahara K, Maruyama Y, Kawabata M, Higuchi I, Kubota H, Izumo S, Arimura K, Osame M. 1996. Therapeutic trials in 200 patients with HTLV-I-associated myelopathy/tropical spastic paraparesis. J. Neurovirol. 2:345-355.
27. Saito M, Nakagawa M, Kaseda S, Matsuzaki T, Jonosono M, Eiraku N, Kubota R, Takenouchi N, Nagai M, Furukawa Y, Usuku K, Izumo S, Osame M. 2004. Decreased human T lymphotropic virus type I (HTLV-I) provirus load and alteration in T cell phenotype after interferon-alpha therapy for HTLV-I-associated myelopathy/tropical spastic paraparesis. J. Infect. Dis. 189:29-40.
28. Yamasaki K, Kira J, Koyanagi Y, Kawano Y, Miyano-Kurosaki N, Nakamura M, Baba E, Suzuki J, Yamamoto A, Yamamoto N, Kobayashi T. 1997. Long-term, high dose interferon-alpha treatment in HTLV-I-associated myelopathy/tropical spastic paraparesis:a combined clinical, virological and immunological study. J. Neurol. Sci. 147:135-144.
29. Bazarbachi A, Plumelle Y, Carlos Ramos J, Tortevoye P, Otrock Z, Taylor G, Gessain A, Harrington W, Panelatti G, Hermine O. 2010. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J. Clin. Oncol. 28:4177-4183.
30. Kinpara S, Hasegawa A, Utsunomiya A, Nishitsuji H, Furukawa H, Masuda T, Kannagi M. 2009. Stromal cell-mediated suppression of human T-cell leukemia virus type 1 expression in vitro and in vivo by type I interferon. J. Virol. 83:5101-5108.
31. Bazarbachi A, El-Sabban ME, Nasr R, Quignon F, Awaraji C, Kersual J, Dianoux L, Zermati Y, Haidar JH, Hermine O, de The H. 1999. Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells. Blood 93:278-283.
32. Bazarbachi A, Nasr R, El-Sabban ME, Mahe A, Mahieux R, Gessain A, Darwiche N, Dbaibo G, Kersual J, Zermati Y, Dianoux L, Chelbi-Alix MK, de The H, Hermine O. 2000. Evidence against a direct cytotoxic effect of alpha interferon and zidovudine in HTLV-I associated adult T cell leukemia/lymphoma. Leukemia 14:716-721.
33. Mahieux R, Pise-Masison C, Gessain A, Brady JN, Olivier R, Perret E, Misteli T, Nicot C. 2001. Arsenic trioxide induces apoptosis in human T-cell leukemia virus type 1-and type 2-infected cells by a caspase-3-dependent mechanism involving Bcl-2 cleavage. Blood 98:3762-3769.
34. Feng X, Heyden NV, Ratner L. 2003. Alpha interferon inhibits human T-cell leukemia virus type 1 assembly by preventing Gag interaction with rafts. J. Virol. 77:13389-13395.
35. Ilinskaya A, Derse D, Hill S, Princler G, Heidecker G. 2013. Cell-cell transmission allows human T-lymphotropic virus 1 to circumvent tetherin restriction. Virology 436:201-209.
36. Jouvenet N, Neil SJ, Zhadina M, Zang T, Kratovac Z, Lee Y, McNatt M, Hatziioannou T, Bieniasz PD. 2009. Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin. J. Virol. 83:1837-1844.
37. Jones KS, Lambert S, Bouttier M, Benit L, Ruscetti FW, Hermine O, Pique C. 2011. Molecular aspects of HTLV-1 entry:functional domains of the HTLV-1 surface subunit (SU) and their relationships to the entry receptors. Viruses 3:794-810.
38. Pique C, Jones KS. 2012. Pathways of cell-cell transmission of HTLV-1. Front. Microbiol. 3:378.
39. Journo C, Mahieux R. 2011. HTLV-1 and innate immunity. Viruses 3:1374-1394.
40. Kannagi M, Hasegawa A, Takamori A, Kinpara S, Utsunomiya A. 2012. The roles of acquired and innate immunity in human T-cell leukemia virus type 1-mediated diseases. Front. Microbiol. 3:323.
41. Delebecque F, Pramberger K, Prevost MC, Brahic M, Tangy F. 2002. A chimeric human T-cell lymphotropic virus type 1 with the envelope glycoprotein of Moloney murine leukemia virus is infectious for murine cells. J. Virol. 76:7883-7889.
42. Pais-Correia AM, Sachse M, Guadagnini S, Robbiati V, Lasserre R, Gessain A, Gout O, Alcover A, Thoulouze MI. 2010. Biofilm-like extracellular viral assemblies mediate HTLV-1 cell-to-cell transmission at virological synapses. Nat. Med. 16:83-89.
43. Kimata JT, Wong FH, Wang JJ, Ratner L. 1994. Construction and characterization of infectious human T-cell leukemia virus type 1 molecular clones. Virology 204:656-664.
44. Chen IS, McLaughlin J, Gasson JC, Clark SC, Golde DW. 1983. Molecular characterization of genome of a novel human T-cell leukaemia virus. Nature 305:502-505.
45. Shimotohno K, Takahashi Y, Shimizu N, Gojobori T, Golde DW, Chen IS, Miwa M, Sugimura T. 1985. Complete nucleotide sequence of an infectious clone of human T-cell leukemia virus type II:an open reading frame for the protease gene. Proc. Natl. Acad. Sci. U.S.A. 82:3101-3105.
46. Derse D, Hill SA, Lloyd PA, Chung H, Morse BA. 2001. Examining human T-lymphotropic virus type 1 infection and replication by cell-free infection with recombinant virus vectors. J. Virol. 75:8461-8468.
47. Journo C, Bonnet A, Favre-Bonvin A, Turpin J, Vinera J, Cote E, Chevalier SA, Kfoury Y, Bazarbachi A, Pique C, Mahieux R. 2013. Human T cell leukemia virus type 2 tax-mediated NF-kappaB activation involves a mechanism independent of Tax conjugation to ubiquitin and SUMO. J. Virol. 87:1123-1136.
48. Mathieu C, Guillaume V, Sabine A, Ong KC, Wong KT, Legras-Lachuer C, Horvat B. 2012. Lethal Nipah virus infection induces rapid overexpression of CXCL10. PLoS One 7:e32157. doi:10.1371/journal.pone.0032157.
49. Laurent AG, Krust B, Galabru J, Svab J, Hovanessian AG. 1985. Monoclonal antibodies to an interferon-induced Mr 68,000 protein and their use for the detection of double-stranded RNA-dependent protein kinase in human cells. Proc. Natl. Acad. Sci. U.S.A. 82:4341-4345.
50. Meertens L, Chevalier S, Weil R, Gessain A, Mahieux R. 2004. A 10-amino acid domain within human T-cell leukemia virus type 1 and type 2 tax protein sequences is responsible for their divergent subcellular distribution. J. Biol. Chem. 279:43307-43320.
51. Bhat NK, Adachi Y, Samuel KP, Derse D. 1993. HTLV-1 gene expression by defective proviruses in an infected T-cell line. Virology 196:15-24.
52. Macchi B, Faraoni I, Zhang J, Grelli S, Favalli C, Mastino A, Bonmassar E. 1997. AZT inhibits the transmission of human T cell leukaemia/ lymphoma virus type I to adult peripheral blood mononuclear cells in vitro. J. Gen. Virol. 78:1007-1016.
53. Nekhai S, Bottaro DP, Woldehawariat G, Spellerberg A, Petryshyn R. 2000. A cell-permeable peptide inhibits activation of PKR and enhances cell proliferation. Peptides 21:1449-1456.
54. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P, Rice CM. 2011. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472:481-485.
55. Cook LB, Elemans M, Rowan AG, Asquith B. 2013. HTLV-1:persistence and pathogenesis. Virology 435:131-140.
56. Datta A, Bellon M, Sinha-Datta U, Bazarbachi A, Lepelletier Y, Canioni D, Waldmann TA, Hermine O, Nicot C. 2006. Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence. Blood 108:1021-1029.
57. Kinpara S, Kijiyama M, Takamori A, Hasegawa A, Sasada A, Masuda T, Tanaka Y, Utsunomiya A, Kannagi M. 2013. Interferon-alpha (IFNalpha) suppresses HTLV-1 gene expression and cell cycling, while IFNalpha combined with zidovudine induces p53 signaling and apoptosis in HTLV-1-infected cells. Retrovirology 10:52.
58. Tattermusch S, Skinner JA, Chaussabel D, Banchereau J, Berry MP, McNab FW, O'Garra A, Taylor GP, Bangham CR. 2012. Systems biology approaches reveal a specific interferon-inducible signature in HTLV-1 associated myelopathy. PLoS Pathog. 8:e1002480. doi:10.1371/journal.ppat.1002480.
59. Goujon C, Malim MH. 2010. Characterization of the alpha interferoninduced postentry block to HIV-1 infection in primary human macrophages and T cells. J. Virol. 84:9254-9266.
60. Garaigorta U, Chisari FV. 2009. Hepatitis C virus blocks interferon effector function by inducing protein kinase R phosphorylation. Cell Host Microbe 6:513-522.
61. Arnaud N, Dabo S, Maillard P, Budkowska A, Kalliampakou KI, Mavromara P, Garcin D, Hugon J, Gatignol A, Akazawa D, Wakita T, Meurs EF. 2010. Hepatitis C virus controls interferon production through PKR activation. PLoS One 5:e10575. doi:10.1371/journal.pone.0010575.
62. Rojas M, Arias CF, Lopez S. 2010. Protein kinase R is responsible for the phosphorylation of eIF2alpha in rotavirus infection. J. Virol. 84:10457-10466.
63. Charoenthongtrakul S, Zhou Q, Shembade N, Harhaj NS, Harhaj EW. 2011. HTLV-I Tax inhibits innate antiviral signaling via NF-{kappa}Bdependent induction of SOCS1. J. Virol. 85:6955-6962.
64. Feng X, Ratner L. 2008. Human T-cell leukemia virus type 1 blunts signaling by interferon alpha. Virology 374:210-216.
65. Oliere S, Hernandez E, Lezin A, Arguello M, Douville R, Nguyen TL, Olindo S, Panelatti G, Kazanji M, Wilkinson P, Sekaly RP, Cesaire R, Hiscott J. 2010. HTLV-1 evades type I interferon antiviral signaling by inducing the suppressor of cytokine signaling 1 (SOCS1). PLoS Pathog. 6:e1001177. doi:10.1371/journal.ppat.1001177.
66. Smith D, Buckle GJ, Hafler DA, Frank DA, Hollsberg P. 1999. HTLVI-infected T cells evade the antiproliferative action of IFN-beta. Virology 257:314-321.
67. Zhang J, Yamada O, Kawagishi K, Araki H, Yamaoka S, Hattori T, Shimotohno K. 2008. Human T-cell leukemia virus type 1 Tax modulates interferon-alpha signal transduction through competitive usage of the coactivator CBP/p300. Virology 379:306-313.
68. Hanon E, Hall S, Taylor GP, Saito M, Davis R, Tanaka Y, Usuku K, Osame M, Weber JN, Bangham CR. 2000. Abundant tax protein expression in CD4+ T cells infected with human T-cell lymphotropic virus type I (HTLV-I) is prevented by cytotoxic T lymphocytes. Blood 95:1386-1392.